Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi.
acute respiratory infections (ARIs)
cost per episode
costs
household costs
respiratory syncytial virus (RSV)
Journal
Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049
Informations de publication
Date de publication:
31 Dec 2020
31 Dec 2020
Historique:
received:
06
08
2020
accepted:
24
11
2020
pubmed:
22
12
2020
medline:
19
8
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness among infants globally, yet economic burden data are scant, especially in low-income countries. We collected data from 426 infants enrolled in the Queen Elizabeth Central Hospital respiratory disease surveillance platform to estimate the household and health system costs of managing RSV and other respiratory pathogens in Malawian infants. Total household cost per illness episode, including direct and indirect costs and lost income, was reported by parents/guardians at the initial visit and 6 weeks post discharge. The total cost to the health system was based on patient charts and hospital expenditures. All-cause acute respiratory infections (ARIs) and RSV costs for inpatient and outpatients are presented separately. All costs are in the 2018 US Dollar. The mean costs per RSV episode were $62.26 (95% confidence interval [CI]: $50.87-$73.66) and $12.51 (95% CI: $8.24-$16.79) for inpatient and outpatient cases, respectively. The mean cost per episode for all-cause ARIs was slightly higher among inpatients at $69.93 (95% CI: $63.06-$76.81) but slightly lower for outpatients at $10.17 (95% CI: $8.78-$11.57). Household costs accounted for roughly 20% of the total cost per episode. For the lowest-income families, household cost per inpatient RSV episode was about 32% of total monthly household income. Among infants receiving care at a referral hospital in Malawi, the cost per episode in which RSV was detected is comparable to that of other episodes of respiratory illnesses where RSV was not detected. Estimates generated in this study can be used to evaluate the economic and financial impact of RSV and acute respiratory illness preventive interventions in Malawi.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness among infants globally, yet economic burden data are scant, especially in low-income countries.
METHODS
METHODS
We collected data from 426 infants enrolled in the Queen Elizabeth Central Hospital respiratory disease surveillance platform to estimate the household and health system costs of managing RSV and other respiratory pathogens in Malawian infants. Total household cost per illness episode, including direct and indirect costs and lost income, was reported by parents/guardians at the initial visit and 6 weeks post discharge. The total cost to the health system was based on patient charts and hospital expenditures. All-cause acute respiratory infections (ARIs) and RSV costs for inpatient and outpatients are presented separately. All costs are in the 2018 US Dollar.
RESULTS
RESULTS
The mean costs per RSV episode were $62.26 (95% confidence interval [CI]: $50.87-$73.66) and $12.51 (95% CI: $8.24-$16.79) for inpatient and outpatient cases, respectively. The mean cost per episode for all-cause ARIs was slightly higher among inpatients at $69.93 (95% CI: $63.06-$76.81) but slightly lower for outpatients at $10.17 (95% CI: $8.78-$11.57). Household costs accounted for roughly 20% of the total cost per episode. For the lowest-income families, household cost per inpatient RSV episode was about 32% of total monthly household income.
CONCLUSIONS
CONCLUSIONS
Among infants receiving care at a referral hospital in Malawi, the cost per episode in which RSV was detected is comparable to that of other episodes of respiratory illnesses where RSV was not detected. Estimates generated in this study can be used to evaluate the economic and financial impact of RSV and acute respiratory illness preventive interventions in Malawi.
Identifiants
pubmed: 33347578
pii: 6042975
doi: 10.1093/jpids/piaa157
pmc: PMC7864144
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
738-745Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.
Références
BMJ Open. 2017 Sep 3;7(9):e017347
pubmed: 28871025
Cost Eff Resour Alloc. 2009 Jan 22;7:3
pubmed: 19161598
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
PLoS One. 2017 Jan 4;12(1):e0168209
pubmed: 28052071
Cost Eff Resour Alloc. 2009 Oct 21;7:16
pubmed: 19845966
BMC Med. 2020 Apr 6;18(1):82
pubmed: 32248817
BMC Public Health. 2015 Apr 07;15:330
pubmed: 25880910
J Infect Dis. 2019 Jan 9;219(3):358-364
pubmed: 30165655
BMC Health Serv Res. 2014 May 22;14:234
pubmed: 24884788
J Infect Dis. 2020 Oct 7;222(Supplement_7):S680-S687
pubmed: 32227101
J Infect Dis. 2016 Dec 1;214(11):1700-1711
pubmed: 27630199
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Lancet Infect Dis. 2017 Nov;17(11):1133-1161
pubmed: 28843578
Lancet Respir Med. 2019 Jan;7(1):69-89
pubmed: 30553848